Who should not take IGF-1 DES?
Documented caution flags for IGF-1 DES include active malignancy and diabetic retinopathy. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for IGF-1 DES is limited.
Documented caution flags for IGF-1 DES
- Active malignancy
- Diabetic retinopathy
- Pregnancy / nursing
Reported side effects to weigh
- Hypoglycemia risk (less than LR3 but real)
- Localized growth at injection site
- Headache
References
- Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats — Tomas FM, Knowles SE, Owens PC, et al., Biochemical Journal, 1992
- Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy — Yoshida T & Delafontaine P, Cells, 2020
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on IGF-1 DES
Last updated 2026-06-15.